Regenxbio DRC A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy with RGX-314 in Subjects with Neovascular AMD (nAMD)
Research Grant
Administered By
Ophthalmology
Awarded By
Regenxbio, Inc.
Start Date
June 21, 2018
End Date
March 31, 2022
Administered By
Ophthalmology
Awarded By
Regenxbio, Inc.
Start Date
June 21, 2018
End Date
March 31, 2022